Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Flemish institute of biotechnology (VIB) | OTHER |
Not provided
Not provided
Not provided
Not provided
The goal of this study is to collect and store human body material (HBM) of patients with amyloidosis in a biobank "BE.Amycon biobank" for future research and to collect clinical data of patients with amyloidosis in a database "BE.Amycon data registry".
With the support of VIB (Vlaams Instituut voor Biotechnologie) Grand Challenges Program, this project aims to establish the BElgian AMYloidosis CONsortium (BE.AMYCON) by joining forces of VIB researchers, a state-of-the-art diagnostic platform, and clinicians from various disciplines and different institutes. Such a consortium will address patient needs and improve outcomes on many levels.
The aim is is to establish a GDPR (General Data Protection Regulation)-proof HBM biobank in the context of amyloidosis. HBM of patients with suspected or confirmed amyloidosis will be prospectively collected and stored for future scientific research. In addition to the HBM collection, a database with personal and health data of patients diagnosed with amyloidosis (any subtype) will be established in order to get better insights on the disease presentation, disease evolution pattern, treatment plans and responses and survival.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Establishment of a data registry: participant baseline demographics | Demographic characteristics of amyloidosis participants will be assessed at baseline. | Baseline |
| Establishment of a data registry: description of the disease characteristics of patients with amyloidosis at diagnosis | Disease characteristics of amyloidosis (disease presentation and symptoms, type of organ involvment, results of diagnostic tests (lab values, imaging, biopsy)) will be collected at moment of diagnosis. | Baseline |
| Establishment of a data registry: treatment in participants with amyloidosis | Description of treatment (type of treatment per line of treatment) of participants with amyloidosis within routine clinical care. | From enrollment of the patient until death, until loss to follow-up or withdrawal of informed consent, whichever comes first, up to 10 years |
| Establishment of a biobank with biological samples (blood, urine, tissue) from patients with amyloidosis | Biological samples (blood, urine, tissue) will be collected from patients with amyloidosis. | From enrollment of the patient until death, until loss to follow-up or withdrawal of informed consent, whichever comes first, up to 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Best Response | Documentation of response rates per line of treatment | From enrollment of the patient until death, until loss to follow-up or withdrawal of informed consent, whichever comes first, up to 10 years |
| Duration of response |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients diagnosed with amyloidosis
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Michel Delforge | Contact | +32 16 346880 | michel.delforge@uzleuven.be |
| Name | Affiliation | Role |
|---|---|---|
| Michel Delforge | UZ Leuven Gasthuisberg | Principal Investigator |
| Joost Schymkowitz, Prof. | VIB - Switch Lab | Principal Investigator |
| Frederic Rousseau, Prof. |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UZ Leuven Gasthuisberg - hematology | Recruiting | Leuven | 3000 | Belgium |
IPD will be available upon signed MTA and DTA and approval by steering committee meeting and ethics committee.
Not provided
Per approved user protocol
upon signed MTA and DTA and approval by steering committee meeting and ethics committee
Not provided
Not provided
| ID | Term |
|---|---|
| D000686 | Amyloidosis |
| D000075363 | Immunoglobulin Light-chain Amyloidosis |
| D028227 | Amyloid Neuropathies, Familial |
| ID | Term |
|---|---|
| D057165 | Proteostasis Deficiencies |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D054219 | Neoplasms, Plasma Cell |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood, urine, biopsy (in the context of amyloidosis), subcuteanous fat aspirate
Duration of response is defined as the time from the date of initial documentation of a response to the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death.
| From enrollment of the patient until death, until loss to follow-up or withdrawal of informed consent, whichever comes first, up to 10 years. |
| Time to Next Treatment (TTNT) | TTNT is defined as the time from the date of initiation of regimen to the initiation of next regimen for each successive therapy received. | From enrollment of the patient until death, until loss to follow-up or withdrawal of informed consent, whichever comes first, up to 10 years. |
| Overall Survival (OS) | OS is defined as the time from the date of initiation of therapy to the date of death from any cause (or last documented follow-up). | From enrollment of the patient until death, until loss to follow-up or withdrawal of informed consent, whichever comes first, up to 10 years |
| Progression-free survival (PFS) | PFS is defined as the time from the date of initiation of therapy to the date of progression or death of any cause, whichever occurs first (or last documented follow-up). | From enrollment of the patient until death, until loss to follow-up or withdrawal of informed consent, whichever comes first, up to 10 years |
| VIB - Switch Lab |
| Principal Investigator |
| UZ Leuven Gasthuisberg - cardiology | Recruiting | Leuven | Belgium |
|
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008232 | Lymphoproliferative Disorders |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
| D010265 | Paraproteinemias |
| D020271 | Heredodegenerative Disorders, Nervous System |
| D019636 | Neurodegenerative Diseases |
| D009422 | Nervous System Diseases |
| D017772 | Amyloid Neuropathies |
| D010523 | Peripheral Nervous System Diseases |
| D009468 | Neuromuscular Diseases |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D028226 | Amyloidosis, Familial |
| D008661 | Metabolism, Inborn Errors |